

Attorney Docket No.: UMD-0070  
Inventors: Langenfeld, John  
Serial No.: 10/044,716  
Filing Date: January 11, 2002  
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A method of reducing vascularization of a tumor in a subject comprising administering to ~~the~~ a subject a therapeutically effective amount of a bone morphogenetic protein-2 (BMP-2) activity inhibitor thereby reducing vascularization of a tumor in the subject.

Claims 2-13 (canceled).

Claim 14 (original): The method of claim 1, wherein the BMP-2 activity inhibitor is administered in a pharmaceutically acceptable carrier.

Claim 15 (canceled).

Claim 16 (currently amended): A method of reducing vascularization of a tumor in a subject comprising administering to ~~the~~ a subject a therapeutically effective amount of an expression vector having a nucleic acid sequence encoding a BMP-2 activity inhibitor and a selective promoter that is operably linked to the nucleic acid sequence thereby reducing vascularization of a tumor in the subject.

Claim 17 (canceled).

Attorney Docket No.: **UMD-0070**  
Inventors: **Langenfeld, John**  
Serial No.: **10/044,716**  
Filing Date: **January 11, 2002**  
Page 3

Claim 18 (original): The method of claim 16, wherein the expression vector is administered in a pharmaceutically acceptable carrier.

Claims 19-20 (canceled).